The characterization of many cytokines involved in the control of hematopoiesis has led to intense investigation into their potential use in ex vivo culture to expand progenitor numbers. We have established the optimum ex vivo culture conditions that allow substantial amplification of transient engrafting murine stem cells and which, simultaneously, augment the ability to sustain serial bone marrow transplantation (BMT). Short-term incubation of unfractionated BM cells in liquid culture with stem cell factor (SCF) and interleukin-1 1 (IL-11) produced a 50-fold amplification of clonogenic multipotential progenitors (CFU-A). Following such ex vivo expansion, substantially fewer cells were required UMAN BONE MARROW (BM), umbilical cord H blood,' and peripheral blood progenitor cells (PBPC) mobilized by chemotherapy andor cytokine treatment' have been shown to be effective sources of primitive hematopoietic stem cells for transplantation following myeloablative therapy. More recently, hematopoietic stem cells manipulated ex vivo have been recognized as candidates for use both for transplantation and for gene therapy protocols. For ex vivo culture, combinations of synergizing growth factors are required to allow stem cell survival and to promote proliferation. Brugger et a13 recently reported the first clinical study of transplantation with progenitor cells generated ex vivo. Following myelosuppressive, but not myeloablative, chemotherapy the ex vivo cultured cells were transfused safely and produced rapid hematologic recovery. However, no conclusions regarding the long-term repopulating ability of these progenitor cells could be drawn from the study.
The characterization of many cytokines involved in the control of hematopoiesis has led to intense investigation into their potential use in ex vivo culture to expand progenitor numbers. We have established the optimum ex vivo culture conditions that allow substantial amplification of transient engrafting murine stem cells and which, simultaneously, augment the ability to sustain serial bone marrow transplantation (BMT) mobilized by chemotherapy andor cytokine treatment' have been shown to be effective sources of primitive hematopoietic stem cells for transplantation following myeloablative therapy. More recently, hematopoietic stem cells manipulated ex vivo have been recognized as candidates for use both for transplantation and for gene therapy protocols. For ex vivo culture, combinations of synergizing growth factors are required to allow stem cell survival and to promote proliferation. Brugger et a13 recently reported the first clinical study of transplantation with progenitor cells generated ex vivo. Following myelosuppressive, but not myeloablative, chemotherapy the ex vivo cultured cells were transfused safely and produced rapid hematologic recovery. However, no conclusions regarding the long-term repopulating ability of these progenitor cells could be drawn from the study.
Exposure of progenitor cells to growth factors may enhance engraftment by two mechanisms. First, such manipulation may provide an increased number of progenitors enriched in transient engrafting potential, and second, may effect the "homing" of stem and progenitor cells to the 3 M microenvironment leading to more rapid engraftment and differentiati~n.~.~ The enhancement of "homing" by shortterm cytokine exposure has recently been disputed by van der Loo and Ploemacher,' who showed, using the cobblestone area forming cell assay (CAFC), that both BM and spleen seeding efficiencies were reduced by preincubation with growth factors. Whether these differences may be explained by choice of growth factors and experimental conditions in these studies is unclear.
An important aim of such ex vivo culture would be to develop conditions that optimize self-renewal of primitive progenitors without terminal differentiation occurring in the short-term. Progenitor populations expanded ex vivo could then be used as the sole source of cells to produce sustained long-term reconstitution following transplantation with potential for use in gene transduction protocols.
In vitro studies of murine hematopoietic stem and progenitor cells have shown that interleukin (1L)-3 or stem cell factor (SCF) are required for survival of dormant primitive to rescue lethally irradiated mice. When transplanted in cell doses above threshold for engraftment, BM cells expanded ex vivo resulted in significantly more rapid hematopoietic recovery. In a serial transplantation model, unmanipulated BM was only able to consistently sustain secondary BMT recipients, but BM expanded ex vivo has sustained quaternary BMT recipients that remain alive and well more than 140 days after 4" BMT. These results show augmentation of both short-term recovery posttransplant and the ability to serially transplant marrow by preincubation in culture with SCF and IL-11. 0 1996 by The American Society of Hematology.
progenitor cells:"' while IL-11, granulocyte colony-stimulating factor (G-CSF), IL-6, and SCF shorten the time that these cells spend in Go.".12 Based on these and other observations, a number of combinations of synergizing cytokines have been investigated that promote extensive amplification of both committed and multipotential progenitors.'0.''.'3-26 Before cloning of SCF, the most potent combination was IL-3 and IL-6," however, the inclusion of SCF promoted even greater stem and progenitor cell amplification and is currently included in most growth factor combinations.
In vivo experiments have been used to assess the effect of cytokine stimulation on long-term repopulating stem cells (LTRC). Several studies report greater recovery of repopulating ability following ex vivo expansion of unfractionated bone marrow compared with purified stem cell popula- 
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expense of stem cell f u n c t i~n , '~.~~ combinations that allow maintenance of LTRC have been determined,'o~'3~'6~*n~z~~~~z8 and in one case a fourfold increase in LTRC was reported when SCF plus IL-I 1 was compared with IL-3 alone. Several studies have shown the ability to transduce murine stem cells with genes of interest in the presence of such synergizing growth factors with efficient infection of reconstituting hematopoietic stem cells in the i~n g -t e r m . '~~'~.~~.~~ The clinical potential of such studies would be greatly enhanced if maintenance or even true expansion of LRTC could be shown, which would permit infusion of expanded populations for rescue following highdose chemotherapy without fear of late graft failure.
One approach to this problem would be to test the longer term engraftment potential after ex vivo expansion in a serial transplantation model that would measure the functional quality of such transplants. In this study, we have attempted to optimize ex vivo culture conditions that allow amplification of murine transient engrafting stem cells, as measured by CFU-A (an in vitro correlate of CFU-S,3n-32) and to assess the effects of such cytokine stimulation on long-term reconstitution in a serial transplantation model. In agreement with other published data,'1"3.25 the combination of SCF and IL-11 produced extensive amplification of short-term engraftment potential. Moreover, the capacity to sustain hematopoiesis over serial transplants was dramatically enhanced suggesting a substantial increase in long-term repopulation potential.
MATERIALS AND METHODS

Conditioned media and growth factors. Recombinant murine
(rm) IL-3 was purchased from R&D Systems (Oxon, UK). R-human (rh) IL-6 was kindly provided by Ares Serono (Geneva, Switzerland). Rh IL-11, rh macrophage colony-stimulating factor (M-CSF), rmGM-CSF (crude conditioned medium derived from COS-1 cells), rhG-CSF, rmSCF (Chinese hamster ovary [CHO] cells) were kindly provided by Genetics Institute (Cambridge, MA). Recombinant human IL-lp was purchased from Genzyme, Cambridge, MA. Erythropoietin was purchased from Boehringer Mannheim Pharmaceuticals, Lewes (East Sussex, UK).
Male and female syngeneic B6D2F1 mice aged 6 to 12 weeks of age were obtained from Harlan Olac Ltd (Shaw's Farm, Bicester, Oxon, UK). BM cells were procured by crushing the femora." For the CFU-granulocyte-macrophage (GM) assay, 5 x lo4 BM cells were added to supplemented alpha minimal essential medium (a-MEM; GIBCO-BRL, Renfrewshire, Scotland 072-2OOOP) with 0.9% methylcellulose (Fluka 64625). 25% donor horse serum (DHS Sigma Chemical CO, Poole, Dorset H7889) and recombinant murine GM-CSF (rmGM-CSF) in 3 cm bacterial grade petri dishes. Granulocyte and macrophage colonies were scored if they contained 2 4 0 cells. The protocol for CFU-A has been described in detail p r e v i o~s l y .~~ BM cells were suspended in a-MEM, supplemented with 25% DHS and the appropriate growth factors, in 24-well plates (Costar, Cambridge, MA) or in tissue culture flasks (Falcon, Becton Dickinson, Cowley, Oxford, UK) at a density of 0.5 X lo6 per mL. Cultures were incubated at 37°C in a fully humidified atmosphere of 5% COz in air. For cultures maintained beyond 7 days, medium and growth factors were replenished at least every 7 days. Following expansion, the cells were procured, washed once in a-MEM and counted using a Coulter counter (Coulter Electronics Ltd, Beds, England).
Female B6D2F1 mice received frac-
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EM transplantation (BMT).
tionated radiation titrated to produce 100% mortality from bone marrow aplasia by day 30. A total of 11.75 to 12.5Gy in two fractions, 3 hours apart, was given at a dose rate of 1.13Gy per minute using a Cobalt-60 source. Fractionated radiation exposure is thought to allow some repair of rapidly proliferating tissues, such as the gastrointestinal tract and lungs.34 Using this protocol, less than 5% of test animals (receiving a cell dose above threshold for engraftment) died before day 7 of radiation toxicity. To assess the engraftment potential of cells expanded ex vivo, an in vivo murine BMT model was developed. It was determined that to ensure >90% survival to day 30 for mice receiving unmanipulated BM cells, a total dose of lo5 cells per mouse was required (data not shown).
The BM infusions were given as a single injection (0.1 mL) via the tail vein 1 hour after irradiation. All animals that received no BM cells died of BM aplasia from days 6 to 18 postirradiation. The ability of expanded populations to sustain hematopoiesis during serial transplantation was assessed by comparing unmanipulated BM cells with BM expanded with SCF and IL-I 1. The initial donor cells were from male B6D2F1 mice, with females as recipients. Primary (1") BMT recipients received a cell dose of 5 X 10' (five times over threshold transplant for 100% survival). For secondary (2") and subsequent BMT, the cell dose was 5 X lo6, which was the maximum cell dose available. To assess both short-term and long-term reconstitution, time points for analysis were at 1 , 3, and 9 months following I" BMT; and at 2 months following 2" BMT. Thereafter, analysis was performed at the time that animals started to show signs of serious malaise or at 3 months following 3" and subsequent BMT. Following 1" and 2" BMT, analyses were performed for full blood count (FBC), femur cellularity, CFU-A content, percentage donor hematopoiesis, and ability to sustain serial transplantation. Following 3" and 4" BMT, animals were followed for survival with limited analysis performed at the time animals started to show signs of serious malaise. Only if an entire group survived beyond 3 months post-BMT was the ability to sustain a serial BMT further assessed.
For the results shown (see Fig 3A and B) , analysis of variance techniques3' were used to examine platelet and neutrophil counts. In each case, residuals were plotted in various ways to determine a transformation that resulted in variance homogeneity and approximate normality. These plots indicated a logarithmic transformation for neutrophil counts and a square root transformation for platelets. The transformed group means were compared at each day using the error estimate from the analysis of variance table. The P values were adjusted using the Bonferroni method36 to allow for multiple comparisons. In the case of the platelet counts, the data for days 14 and 18 appeared markedly more variable than at other time points, and these observations have not been included in the main analysis.
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RESULTS
Ex vivo expansion of unfractionated bone marrow cells.
The amplification factors for CFU-A following a 6-day incubation in serum_ containing medium with a wide range of cytokines are shown in Fig 1. The most impressive amplification was consistently obtained with SCF and IL-11, although this was not significantly greater than SCF with IL-10, IL-6 or G-CSF. None of the combinations using three or more growth factors resulted in greater amplification than with SCF plus E-11. Subsequent experiments with this growth factor combination, designed to determine the time at which the stem cell pool was exhausted, showed that these expansion cultures could be continued for up to 30 days, by which time increases in the absolute numbers of CFU-A were no longer observed. Total CFU-A amplification reached a plateau at about 1,000-fold on day 30. The plating efficiency for CFU-A increased from 0.15% on day 0 to peak at 5.8% by day 6. Therefore, these cultures do truly expand over the first 2 weeks and do not appear to exhaust before day 30. These results. therefore, show a profound ability of the SCF and IL-I 1 cytokine combination to expand the transient engrafting stem cell compartment ex vivo over a long period of time.
A significant survival advantage for mice receiving expanded BM was shown using limiting dilution (Fig 2) . Mice receiving cells expanded ex vivo showed a significant improvement in survival to day 30 compared with those receiving unmanipulated BM cells at all four cell doses (P = .0001 to .046, Student's paired ttest, 2-tailed). These marked differences in survival for an expanded versus unmanipulated BMT indicate that this advantage is mediated by the ex vivo expanded transient engrafting cells detected by the CFU-A and GM-CFC assays.
Having shown that expanded populations gave rise to improved survival as a function of transplanted cell number compared with unmanipulated cells, it was then important to determine whether expanded transplants gave rise to faster engraftment. To exclude an effect simply because of cell number input, all mice were transplanted with cell doses at least fivefold greater than the rescue threshold for unmanipulated BM cells. It is well established that using cell doses vastly in excess of the determined threshold value does not further enhance the rate of engraftment.." Therefore, any effects on the speed of engraftment should reflect a qualitative enhancement of engraftment for expanded cells, rather than any cell dose effect. The short-term marrow repopulating ability was assessed by PB counts as shown in Fig 3A and B. Mice receiving unmanipulated BM cells and mice receiving SCF/ IL-I I expanded BM marrow cells were neutropenic by day Short-term survival following BMT.
Short-term engrqftmerit .following BMT.
3 following radiation. On day 5 following radiation, the mean neutrophil count was significantly higher in mice transplanted with BM cells expanded ex vivo with SCF and IL-I 1 than for mice transplanted with unmanipulated BM cells (P = .002). Thereafter, from day 5 to day 1 I , the differences in neutrophil counts between animals transplanted with expanded versus unmanipulated BM were highly significant and in favor of ex vivo expansion (P < .001 on days 7, 9, and 1 I). By day 14, the neutrophil counts were still higher for animals transplanted with expanded cells, but this difference was no longer of statistical significance ( P = ,029). The platelet nadir was significantly less severe for mice transplanted with cells expanded ex vivo with SCF and IL-1 I (P < .001). Thereafter, platelet recovery was more rapid for animals that received expanded BM (P < ,001 on day I I). These significant effects on both neutrophil and platelet recovery suggest that ex vivo culture of BM cells with this cytokine combination mediates a qualitative influence on progenitor homing or maturation independent of the small total cell number increase that occurs over the duration of culture.
The effect of expansion on the long-term repopulating stem cell pool was tested using serial transplantation. Serial BMT is known to lead to an eventual loss of the long-term repopulating capacity of BM Serial BMT experiments were then used to stress the transplanted stem cell population and to compare unmanipulated with SCF and IL-I 1 expanded BM for their ability to sustain serial BMT, as a good functional test of the long-term repopulating cell. Serial transplantation was performed as described in Materials and Methods. At I, 3, and 9 months following I" BMT and at 2 months following 2" BMT, analyses showed no differences between the animals transplanted with unmanipulated BM cells and those Sericil RMT rind long-term reconstitution. that received expanded cells. It is clear from Table 1 , that unmanipulated BM cells could not sustain serial transplantation as evidenced by CFU-A numbers. In contrast, the marrow expanded with SCF and IL-11 showed a significantly higher CFU-A profile through tertiary recipients. All animals HOLYOAKE ET AL The figures in parentheses in column 1 represent the time of analy-* Subsequently used for quaternary BMT.
t Analyzed at the time of bone marrow failure.
* Subsequently used for quaternary BMT.
sis post-BMT.
surviving long-term after tertiary BMT showed evidence of donor hematopoiesis (data not shown). Three groups were tested for ability to sustain a quaternary BMT (see Table 1 , groups* and *). As shown in Fig 4 (group*), unmanipulated marrow was unable to sustain hematopoiesis beyond day 30, and no further analyses were performed on these animals.
In marked contrast, the recipients of SCF/IL-1 1 -treated marrow remained alive and well at >200 days post-4" BMT. The final group, derived from initial recipients of expanded BM and subsequently tested in a fourth BMT (group*) were still surviving at >200 days post-BMT. 3" recipients of transplants derived from primary recipients of unmanipulated BM (Table 1 , group'), developed BM failure with only 9 animals surviving to day 95. These nine animals were analyzed and had pancytopenia and insufficient cells to allow 4" BMT. These experiments show that unmanipulated marrow is For personal use only. on August 16, 2017. by guest www.bloodjournal.org From able to sustain 2" BMT, but either fails during 3" BMT or is unable to sustain 4" BMT. In contrast, SCF/IL-ll expanded marrow has consistently been able to sustain 4" BMT to well beyond 200 days post-BMT.
DISCUSSION
In this study, we have developed optimal culture conditions for the ex vivo expansion of progenitors responsible for the transient phase of engraftment following BMT in mice and have assessed the effect of such cytokine stimulation on long-term reconstitution in a serial transplantation model. The choice of cytokine combinations for investigation included both stromal derived factors and early acting factors, which might restrict the degree of differentiation but, at the same time, allow proliferation of progenitor populations. The cytokine combination of SCF and IL-11 gave rise to a 50-fold amplification of transient engrafting stem cells by day 6. The addition of multiple cytokines, both early and later acting, did not further improve the degree of ex vivo expansion achieved. In cultures maintained beyond day 30, an eventual depletion of amplification ability of clonogenic cells occurred. However, in a clinical setting, a relatively short period of ex vivo expansion (4 to 14 days) to allow amplification of those progenitors responsible for transient engraftment would be well suited to current chemotherapy and radiation conditioning regimens for transplantation. Thus, the culture conditions we describe should prove a good model for the clinical manipulation of human progenitors.
We have assessed the engrafting potential of the expanded population in three different ways. In the first approach, the lethally irradiated recipients received dose-limiting transplants of expanded cells that resulted in survival with 10-fold to 20-fold fewer starting cells than mice receiving unmanipulated marrow. Because the total cell number increase in ex vivo cultures is only modest (onefold to twofold over 6 days) this improvement in survival could not be due solely to an increase in the total number of cells transplanted, but must relate either to the increased concentration of CFU-A progenitors (50-fold increase over 6 days) and/or to effects on progenitor "homing." All animals surviving to day 30 in these experiments were followed for 1 year after BMT. There were no cases of late BM failure, and at 1 year there was consistent evidence of donor hematopoiesis (data not shown). This result has important potential implications for clinical transplantation, since, for autologous BMT, there are often situations when the threshold cell number cannot be obtained either from BM or by leukapheresis. The ability to use one tenth or less of a standard transplant cell dose would reduce the risk of tumor cell contamination by at least one log.
In our second approach the quality of engraftment was assessed using cell doses in excess of the threshold required for engraftment. SCF/IL-1 1 expanded BM gave rise to significantly faster hematologic recovery in terms of hemoglobin, platelets, and neutrophils. This has previously been shown for other cytokine combination^^^^^'*^^ and therefore is not specific to the growth factor combination used in this work. It is generally accepted that transplantation with cell doses well in excess of the threshold for hematopoietic rescue cannot further hasten hematological recovery.37 Therefore, it appears that cytokine exposure may reduce the time required for progenitors to home adequately to the bone marrow and/or spleen and to produce functional mature blood cells. The homing of hematopoietic progenitor cells, before and after cytokine exposure, may relate to changes in the level of expression of a variety of adhesion moletules . 4-7.43.44 In these two series of transplantation experiments, we have demonstrated convincingly that transient engrafting stem cells can be expanded ex vivo and that, following their transplantation in vivo, the kinetics of engraftment are favorably influenced.
A fundamental question in studies of this type is whether expansion of stem and progenitor cells ex vivo can occur without reducing the proliferative capacity of the stem cell compartment in the long-term. Our results demonstrate serial BMT using expanded populations well beyond that possible with unmanipulated BM. Although these results suggest that ex vivo culture of BM cells in the presence of SCF and IL-11 leads to the expansion of the most primitive stem cells, the long-term repopulating stem cells, this cannot be proven by these studies and would require quantitative stem cell assays. An alternative explanation implicating a critical time between transfers would be that following BMT with expanded populations, engraftment is more rapid than for unmanipulated BM and, therefore the ability to serially transplant marrow is regained in a shorter period of time. This would be in agreement with the work by Jones et a140 in which they showed that the ability to sustain serial BMT was influenced by both cell dose and the interval between cell transfers. If the interval between transfers were increased from 1 month to 6 months, then unmanipulated BM was better able to sustain serial BMT. 40 In our study, the normal ratio of committed to LTRC may be established more quickly with expanded than with unmanipulated marrow after 1" BMT. This more rapid establishment of functional long-term repopulating cell populations in mice receiving expanded BM compared with normal BM may, in turn, account for the improved serial transplantation potential. These studies underline the need to examine the effect of intervals between transplants in models of this type.
It is most likely that primitive stem cells must enter cell cycle during the ex vivo expansion conditions used in our studies. Therefore, while we do not claim self renewal of long-term repopulating stem cells, we have clearly been able to induce an expansion of transient engrafting stem cells and a corresponding improvement in the functional ability of more primitive cells. The ability of expanded populations to sustain serial BMT beyond that of unmanipulated bone marrow is a very significant finding that deserves further investigation. Therefore, these studies have implications not only for transplantation studies in the clinic, but may also be of significance to gene marker and gene therapy studies in the hematopoietic system. For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
